Friday, February 23, 2024 |

RNAimmune secures $27M in Series A financing

March 31, 2022

RNAimmune Inc., a biopharmaceutical company in Gaithersburg specializing in discovery and development of mRNA-based therapeutics and vaccines, announced Wednesday it has secured $27 million in a Series A round of financing. The company intends to use the funding to accelerate its research and development of mRNA vaccine and drug discovery focused on infectious disease, cancer, and rare diseases.

Article Source: The Daily Record

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.